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The varied forms of leprosy form a spectrum (1), with the paucibacillary
tuberculoid leprosy at one pole manifesting good cell-mediated immunity (CMI).
The multibacillary lepromatous leprosy, at the other extreme, is associated with
poor Tcell responses. Studies on the role of Ts cells in the understanding ofthe
selective Mycobacterium leprae-related T cell anergy in lepromatous leprosy have
led to conflicting results. Whereas Mehra et al. (2), using a costimulant assay,
indicated that 84% of lepromatous leprosy patients had lepromin-induced
OKT8+ Ts cells that inhibited in vitro Con A responses, repeated studies from
our laboratory (3, 4) as well as others (5-8) using similar assays and modified
protocols failed to confirm these findings. Recent evidence from Mehra et al. (9)
indicated that the unique antigen phenolic glycolipid-I (PGL-I) may be a major
suppressor molecule on M. leprae capable of inducing suppressor cells in lepro-
matous patients. Furthermore, vaccinated patients were shown to have reversal
of suppression, implicating thereby a pathogenetic association to this in vitro
phenomenon (9). In the present investigation, we provide the first evidence that
PGL-I induces a general suppressive effect on mitogenic responses across the
leprosy spectrum and is not unique to the lepromatous leprosy type. Moreover,
this antigen used in identical concentrations has both a stimulatory and suppres-
sive role in some healthy and lepromatous subjects.
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Materials and Methods
BriefDefinitive Report
Patients.
￿
We included 42 leprosypatients in this study, including 15just diagnosed as
having bacilliferous lepromatous (2BL, 13LL), 9 treated for bacilli negative lepromatous,
18 tuberculoid patients (15 BT, 3TT),and 11 healthy contacts (6 ofwhom were exposed
to leprosy patients for >5 yr) attending the leprosy clinics in Delhi (Safdarjung Hospital).
The leprosy patients were classified on the basis of the Ridley andJopling scale (1) after
clinical and histopathological examination. The bacillary load (BI) was evaluated by slit
smear examination and Ziehl-Neelsen staining ofthree to six sites in the body (10). The
treated patients had been mainly on dapsone (4,4'-diamino diphenyl sulfone; DDS)
monotherapy for >5 yr. The other patients were either just diagnosed or on <1 yr of
dapsone therapy.
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Stimulants.
￿
Integral M. leprae bacilli were extracted from human lepromas, heat killed,
and used at an optimal concentration of 5 X 106 bacilli/ml in lymphoproliferative and
suppressor assays as described earlier (3).
PGL-I was kindly donated by Dr. P. J. Brennan (Dept. of Microbiology, Colorado State
University, Fort Collins, CO) and Mrs. Sheila Payne, National Institute for Medical
Research, London, United Kingdom. Because of its insolubility in aqueous media, it was
incorporated into liposomes (11). Briefly, a mixture of 1 mg PGL-I, 8.67 mg sphingomye-
lin, 3.16 mg cholesterol, and 0.28 mg dicetyl phosphate (Sigma Chemical Co., St. Louis,
MO) were dissolved in chloroform and methanol (2:1) and dried in an air stream at 37°C.
1 ml of RPMI 1640 (Gibco Laboratories, Irvine, United Kingdom) was added and
sonicated in a Branson sonifier (Branson Cleaning Equipment Co., Shelton, CT) cold
water bath for 1 h . They were stored at 4 ° C and resonicated before use. The incorporation
of PGL-I in liposomes was checked by (1) immunodiffusion in 1% agar using varying
dilutions of mAb to PGL-I (12), kindly donated by Dr. D. B. Young (MRC Unit in
Tuberculosis and Related Mycobacterial Diseases, Hammersmith Hospital, London,
United Kingdom), and (2) agglutination in 96-well microtiter plates using checkerboard
titration with one-fourth, one-eighth, and one-sixteenth dilution of stock PGL-I incorpo-
rated and control liposomes with doubling dilutions of (a) anti-PGL mAb and (b) pooled
lepromatous sera containing anti-PGL antibodies.
Control liposomes devoid of PGL-I were prepared in a similar manner and used in
similar concentrations in parallel replicate cultures.
Con A (Pharmacia Fine Chemicals, Uppsala, Sweden) was found to optimally stimulate
PBMC of normal subjects at a concentration of 10 pg/ml.
Lymphoproliferation.
￿
PBMC were separated by Ficoll-Hypaque (13) density gradients
(Pharmacia Fine Chemicals, Uppsala, Sweden) from sterile heparinized blood (10 units of
heparin per ml of blood; The Upjohn Co., Kalamazoo, MI) and put up for culture in
RPMI 1640 + 10% AB serum as described earlier (3). In brief, 105 cells in 100 jul
medium/well were dispensed in 96-well round-bottomed microtiter plates (Nunc In-
termed, Kamstrup, Denmark). Four replicates each were set up with (a) cells only and
cells with 25 ul of (b) M. leprae, (c) varying concentrations of PGL-I liposomes, and (d)
similar concentrations of control liposomes devoid of PGL-I. The cultures were incubated
at 37 °C with 5% C02 and air. They were terminated on day 6, except where stated after
18 h of pulsing with 1 uCi ['H]thymidine (2 Ci/mmol, Bhabha Atomic Research Centre,
Trombay, India). Cultures were harvested on glass fiber discs using a semiautomatic cell
harvester (PHD, Cambridge, MA) and processed for liquid scintillation counting in an
LKB Rackbeta 1712, Turku, Finland. Stimulation index was expressed as: (a) (mean cpm
of cells with M. leprae)/(mean cpm of cells only), (b) (mean cpm of cells with PGL-I
liposomes)/(mean cpm of cells with control liposomes).
Suppressor Cell Activity.
￿
Antigen-induced suppressor cell activity on mitogen responses
was undertaken as described earlier (3). Cultures were set up as above with (a) medium
only and 25 kl of the stimulants (b) Con A, (c) M. leprae, (d) PGL-I liposomes (1 ug/ml,
except where stated), (e) control liposomes ofappropriate dilution, (f) Con A + M. leprae,
(g) Con A + PGL-I liposomes, (h) Con A + control liposomes. The cultures were incubated
as above and terminated on day 3 after 18 h of pulsing with [6H]thymidine. A cpm of
replicate cultures were calculated as (a) [(mean cpm of cells with Con A or M. leprae) -
(mean cpm of cells alone)], (b) [(mean cpm of cells with PGL-I liposomes) - (mean cpm of
cells with control liposomes)]. Percent suppression induced by antigens M. leprae and
PGL-I liposomes was expressed as: 100 X [1 - (mean A cpm of cultures with antigens +
Con A)/(mean A cpm of cultures with Con A)]. 10% inhibition/enhancement was found
to be statistically significant (p <0.05).
Statistical Analysis. Mann-Whitney U test and Kruskal Wallis tests were used for
calculating p values (14).
Results
Since PGL-I is insoluble in aqueous medium it was presented to PBMC in the
liposomal form. The definitive presence of PGL-I in liposomes was established
by screening with pooled lepromatous sera containing anti-PGL antibodies andPRASAD ET AL. BRIEF DEFINITIVE REPORT
TABLE I
Stimulation Index* and Effect ofM. leprae and Phenolic Glycolipid-I (PGL-I) on
Con A Responses
24 1
* Stimulation index, (Mean cpm of cells with M. leprae or PGL-I liposomes)/(Mean cpm of cells alone or cells with
control liposomes).
$ Figures in parentheses indicate number of patients.
an mAb to PGL (12). At 1/8 dilution of stock liposomes prepared from 1 mg/ml
of PGL-I, agglutination was observed at 1/32 and 1/320 dilution of pooled
lepromatous sera and the mAb, respectively. Furthermore, immunodiffusion in
agar using the mAb gave a strong precipitin line.
PGL-I-Induced Lymphoproliferation.
￿
We evaluated the ability of PGL-I lipo-
somes to stimulate PBMC from leprosy patients and healthy lepromin responsive
contacts (Table I) . Over a concentration range of 0 .25-10 ug/ml PGL-I, no
stimulation was observed in 20 lepromatous leprosy patients. In contrast, 6 of 9
tuberculoid patients and 5 of 11 healthy subjects had significant lymphoprolifer-
ation over a 1-10 Ag/ml range, with a stimulation index range of 2.3-8.0. The
time kinetics of PGL-I-induced lymphoproliferation was similar to that of integral
M. leprae, with maximal [3H]thymidine incorporation seen on day 6 .
Suppression ofCon A Responses in Vitro.
￿
Over a concentration range of 0 .25-
10 mg/ml of PGL-I, optimal in vitro suppression of Con A responses was seen at
1 mg/ml in six responder subjects and subsequent studies were undertaken at
this concentration.
Significantly increased (p <0.05 to <0.01) levels of suppression of lymphopro-
liferation to Con A was induced by PGL-I liposomes as compared with M. leprae
in many leprosy patients. The percent suppression ranged from 13-64% and
12-79% in untreated lepromatous and tuberculoid patients, respectively. Both
the number of individuals showing suppression as well as the level of suppression
was increased in the presence of PGL-I. This feature was observable across the
leprosy spectrum; 9 of 15 untreated lepromatous (p <0.05) and 10 of 18
tuberculoid patients (p <0.01) showed significantly higher levels of suppression
of mitogenic responses by PGL-I as compared with M. leprae. The level of
inducible suppression was unrelated to the background Con A responses (Table
I) . To evaluate the temporal nature of the suppression we studied nine treated
lepromatous patients who were devoid of bacilli in the skin . None of them
showed PGL-I-induced suppression.
Moreover, at the same concentration, PGL-I showed both stimulatory and
inhibitory effects on Con A responses of lepromatous and healthy subjects but
not in any of the tuberculoid patients.
In agreement with our earlier studies (3), we also found that M. leprae-induced
suppression was infrequent in untreated lepromatous (13%) and more common
in the tuberculoid (67%) and healthy responder (54%) individuals. Interestingly,
Stimulation index Mean cpm (range) of Con A cultures
Leprosy type (range)
M. leprae PGL-1 + M. leprae + PGL-1
Tuberculoid (18)$ 2.3-8.0 2.3-6.3 (9)# 10,560-82,983 2,337-74,128 1,464-81,827
Healthy (11) 2.0-4.2 1 .5-2.4 (11) 25.664-50,523 4,818-34,406 3,572-59,327
Treated Lepromatous (9) 0.8-1 .6 1.3-1.7 (7) 47,520-89,669 44,966-142,080 50,776-73,783
Untreated Lepromatous (15) 0.6-1 .4 0.8-1 .9 (13) 1,486-33,720 1,424-40,561 1,180-48,447242
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FIGURE 1 . The effect of PGL-incorporated liposomes and integral M. leprae on Con A-
inducedresponses of PBMC. 15 untreated and 9 treated lepromatous, 18 tuberculoid and 11
healthy subjects were studied. Each bar indicates an individual subject tested concurrently
with PGL (p) and M. leprae (l). Using a 3-d costimulant assay (3), four replicates of 105
cells/well of Ficoll-Hypaque-purified PBMC were cultured in 96-well microtiter plates with
Con Aalone and with Con A + antigens. Cells alone and cells with liposomesdevoid of PGL
were used as controls for the appropriate experiments. % suppression = 100 X 1 - [(mean
cpm of PBMC + Antigen+ Con A)/(mean cpm of PBMC + Con A)]. 0 cpm = (a) (mean cpm
of PBMC with ML or Con A) - (meancpm of PBMC alone) and(b) (mean cpm of PBMC with
PGL-I liposomes) - (mean cpm of PBMC with control liposomes). Dashed lines indicate ±
10% used as cutoff point based on p <0.05as evaluated by two-way analysis of variance. The
p values forsignificance of suppression (Kruskall-Wallis test) are: M. leprae antigen, <0.01 for
tuberculoid vs. untreated lepromatous and <0.05 for vs. treated lepromatous patients; PGL
antigen, <0.05 for tuberculoid vs. untreated lepromatous and <0.001 vs. treated lepromatous
patients; PGL vs. M. leprae, <0.05 for untreated patients, and <0.01 fortuberculoid patients.
4 of 6 healthy laboratory staff members showing in vitro suppression in the
presence of M. leprae had been exposed to leprosy patients for more than 5 yr.
Except for one, all the others showing lack of suppression had been in contact
with leprosy patients for <_2 yr.
Discussion
The present study indicates that PGL-1 liposomes are potent inducers of
suppression of Con A responses across the leprosy spectrum. The suppression
induced by the glycolipid is seen in 60% of lepromatous patients and parallels
that seen in tuberculoid leprosy (67%). Though the number of tuberculoid
patients showing significant suppression to both antigens was the same, the level
of suppression exerted by PGL-1 was significantly higher (p <0.05 to <0.01, Fig.
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1). Interestingly, lepromatous patients with undetectable bacillary load subse-
quent to prolonged chemotherapy showed reversal ofsuppression.
This antigen also stimulated lymphoproliferation in responder patients and
healthy population with similar time kinetics as integral M. leprae antigens.
Paradoxically, at the same concentration PGL-I had both a stimulatory and
suppressive role in some lepromatous and healthy subjects.
In confirmation of our earlier studies (3), integral M. leprae-induced suppres-
sion ofCon A responses was lower in lepromatous as compared with tuberculoid
leprosy and healthy lepromin responder subjects. Moreover, in agreement with
studies of Stoner et al. (15), the healthy laboratory staff members showing in
vitro induced suppression had been in contact with leprosy patients for 5 yr,
whereas all except one showing no evidence ofsuppression had recent exposure
of 1-2 yr. We have interpreted these results to indicate that a well-regulated T
cell-mediated immune response resulting from natural exposure to M. leprae as
in the healthy staff members or limited infection as in tuberculoid patients may
induce a parallel Ts cell function as part ofa physiological response.
The proposed roleofPGL-I as a unique suppressorepitope (9) appears unlikely
to be the central mechanism responsible for the antigen-specific anergy peculiar
to lepromatous leprosy. Several points appear to disfavor its singular role in the
biology of the disease: (a) the same molecule at the same concentration has both
a stimulatory and inhibitory effect in some subjects, (b) in ^-60% ofcases it shows
a general in vitro suppressive effect in both the localized and disseminated forms
of leprosy, (c) moreover, the reversal of in vitro suppression induced by PGL-I
in long term-treated bacilli-negative lepromatous patients is not accompanied by
improvement in their antigen-specific anergic state or a return to skin test
reactivity. Nevertheless, it is possible that the observed accumulation of PGL-I
in the tissues of bacilliferous lepromatous leprosy patients may help to protect
the M. leprae organism within the host macrophages or play a role in the
secondary depression of general T cell responses seen in some lepromatous
patients or contribute to the immunopathology of the lesions.
Other suppressive mechanisms need to be explored to explain the wide
spectrum ofclinicopathological features seen in leprosy and the antigen-specific
anergy associated with lepromatous leprosy. Our earlier data suggested that
monocytes of lepromatous patients released suppressive factors on contact with
antigen (16) that inhibited IL-2 production (17).
Summary
Using a costimulant assay, in vitro Con A responses of patients across the
leprosy spectrum were found to be markedly suppressed by phenolic glycolipid-
I (PGL-I), a unique antigen of M. leprae . The degree ofinducible suppression as
wellasthe number ofleprosypatients showing suppression ofmitogenic responses
was higher with PGL-I as compared with integral M. leprae (p <0.05 to <0.01).
Both untreated lepromatous (60%) as well as tuberculoid leprosy (67%) patients
showed significant suppression ranging from 13 to 64% and 12 to 79%, respec-
tively. Thus, PGL-I appears to have a universal suppressive effect on Con A
responses and is unlikely to play a central role in determining the leprosy
spectrum.
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